Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Journal of Dermatological Treatment|May 15, 2024
Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United StatesMaryia Zhdanava, Timothy Fitzgerald, Dominic Pilon, et al.
Psychology & Health|October 6, 2016
Motivational interviewing or reminders for glaucoma medication adherence: Results of a multi-site randomised controlled trialPaul F Cook, Sarah J Schmiege, Steven L Mansberger, et al.
Dermatology and Therapy|December 30, 2022
Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis RegistryApril W Armstrong, Timothy Fitzgerald, Robert R McLean, et al.
Advances in Therapy|March 17, 2023
The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis RegistryApril W Armstrong, Timothy Fitzgerald, Robert R McLean, et al.
Dermatology and Therapy|December 9, 2022
Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis RegistryApril W Armstrong, Timothy Fitzgerald, Robert R McLean, et al.
Archives of General Psychiatry|October 3, 2012
The associations of insomnia with costly workplace accidents and errors: results from the America Insomnia SurveyVictoria Shahly, Patricia A Berglund, Catherine Coulouvrat, et al.
Sleep|June 2, 2012
Insomnia, comorbidity, and risk of injury among insured Americans: results from the America Insomnia SurveyRonald C Kessler, Patricia A Berglund, Catherine Coulouvrat, et al.
Journal of Drugs in Dermatology : JDD|August 7, 2025
Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis PatientsBruce E Strober, Jud C Janak, Timothy Fitzgerald, et al.
Dermatology and Therapy|June 11, 2025
Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis RegistryApril W Armstrong, Steven R Feldman, Timothy Fitzgerald, et al.
Experimental Hematology & Oncology|November 22, 2014
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trialTeresa Moran, Enriqueta Felip, Vicki Keedy, et al.
Pageof 4